Table 2.

Clinical trials of thrombolytic agents including elderly patients

							Result of primary outcome
Study	Agents and daily dose	Follow-up	Elderly participants	Women	Inclusion criteria	Primary outcome measures	Incidence in active group	Incidence in placebo group	ARR P value
GISSI [14]	Streptokinase 1.500.000 U vs. placebo	21 days	65–75 years (24.6%)>75 years (10.3%)	19.7%	MI within 12 h of symptom onset	All-cause mortality	10.7%	13.0%	2.3%P = 0.0002
ISIS-2 [18]	Streptokinase 1.500.000 U vs. aspirin 160 mg vs. both	5 weeks	60–69 years (35.2%)≥70 years (19.8%)	22.9%	MI within 24 h of symptom onset	Vascular mortality	9.2%	12.0%	2.8%P < 0.00001
ASSET [19]	rt-PA 100 mg + heparin vs. placebo + heparin	1 month	>65 years (33.5%)	23.0%	MI within 5 h of symptom onset	All-cause mortality	7.2%	9.8%	2.6%P = 0.0011
AIMS [17]	APSAC 30 U vs. placebo	1 month	≥60 years (39.9%)	NA	MI within 6 h of symptom onset	All-cause mortality	6.4%	12.2%	5.8%P = 0.0016
GUSTO-I [20]	Streptokinase 1.500.000 U + heparin s.c or streptokinase 1.500.000 U + heparin i.v. or accelerated TPA + heparin i.v. or streptokinase 1.500.000 U + accelerated TPA + heparin i.v.	1 year	65–74 years 27.3%75–85 years 11.3%>85% years 1.0%	25.0%	MI within 6 h of symptom onset	All-cause mortality at 30 days and 1 year	6.3% (t-PA)	7.4% (streptokinase)	1.1%P = 0.001

MI, myocardial infarction; NA, not available; ARR, absolute risk reduction.